title: CD151 expression can predict cancer progression in clear cell renal cell carcinoma.
abstract: OBJECTIVE
  CD151 is known to be implicated in cancer progression and metastasis. The aim was to evaluate the expression of CD151 in clear cell renal cell carcinoma (CCRCC) and to assess its prognostic significance.
  
  
  RESULTS
  The expression of CD151 was evaluated in 489 cases of CCRCC by immunohistochemistry. Immunoreactivity was classified into four categories (minimal, 0-10% positive cells; focal, 10-50% positive cells; diffuse moderate, >50% positive cells with moderate staining intensity; diffuse strong, >50% positive cells with strong staining). To determine the statistical significance of CD151 expression in CCRCC, all cases were divided into two groups based on their CD151 expression level: a CD151-low group (n=257; minimal and focal) and a CD151-high group (n=232; diffuse). Expression of CD151 was correlated positively with pT, pN, pM categories, pathological tumour-node-metastasis (pTNM) stage, nuclear grade, tumour size and patient's age. The CD151-high group had significantly shorter cancer-specific survival (P<0.001) and progression-free survival (P<0.001) times. Furthermore, multivariate analysis showed that CD151 expression was an independent predictor for tumour progression in patients with CCRCC (P=0.040).
  
  
  CONCLUSIONS
  High CD151 expression is associated with advanced stage and high nuclear grade in CCRCC. CD151 is a prognostic marker for tumour progression in CCRCC patients.
authors.affiliation: Department of Forensic Medicine and Institute of Forensic Medicine, Medical Research Center, Seoul National University College of Medicine, Seoul, Korea.
authors.forename: Seong H
authors.initials: SH
authors.lastname: Yoo
authors.forename: Kyoungbun
authors.initials: K
authors.lastname: Lee
authors.forename: Ji Y
authors.initials: JY
authors.lastname: Chae
authors.forename: Kyung C
authors.initials: KC
authors.lastname: Moon
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015703:Antigens, CD / Q000096:biosynthesis*; D014408:Biomarkers, Tumor / Q000032:analysis*; D002292:Carcinoma, Renal Cell / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D007680:Kidney Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D060185:Tetraspanin 24; D046888:Tissue Array Analysis; D055815:Young Adult
chemical_list: D015703:Antigens, CD; D014408:Biomarkers, Tumor; C554715:CD151 protein, human; D060185:Tetraspanin 24